MNPR · Monopar Therapeutics
$113.72
+2.90 (+2.62%)
At close · Aug 26
Market Cap
$745.55M
Shares
6.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$113.72
Open$111.26
Day$108.22–114.75
52W close$32.03–123.84
Avg vol 30d265K
Short int887K · 13.2% float · 3.5d
Short vol73%
DataAug 2024–Aug 2026
Filing10-Q · Aug 12
Raw chart and full-history price indicators begin at the captured split on Aug 13, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+54%
above
Price vs 50-day avg
+10%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
89%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+104%
trailing
YTD return
+74%
this year
Relative strength
+91%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $104 › 200d $74 — 50d above 200d
Institutional flow
Accumulating
+16% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.22% of float · ▼ -16.7% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
95 holders — near 3-yr high, broad support
Squeeze score
70
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+54%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
89%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $104 › 200d $74 — 50d above 200d
Institutional flow
Accumulating
+16% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.22% of float · ▼ -16.7% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
95 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $32
Now $114 · 89%
Range high $124
vs 200-day avg +54%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MNPR
this stock
Monopar Therapeutics
|
$745.55M | +74.2% | — | — | 13.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Aug 13, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MNPR | -8.2% | +5.9% | +103.8% | +5.0% | +74.2% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -7.8% | +0.8% | +91.4% | +2.4% | +61.8% |
Key facts
CIK
1645469
CUSIP
61023L207
13F (30d)
93 filings
92 filers
Visit website
Investor relations